“A core outcome set (COS) is an agreed standardised set of outcomes that should be measured and reported, as a minimum, in all clinical trials in specific areas of health or health care.”
This clarifies directly what the COMET initiative is about. But it also leaves open a lot of questions such as:
[Read more…] about Core Outcome Measures in Effectiveness Trials – COMETThe Introduction to Industry Training (ITIT) gives the delegates a taste of life across the pharmaceutical industry from early drug discovery to marketing, from CRO to Big Pharma and across the UK and continental Europe. The course aims to show the delegates the breadth and depth of work that goes on the industry and give them ideas of where they can get involved. PSI organized this course into 6 two-day sessions, each covering a stage of drug development and each hosted at a different company. The host company will give their unique perspective from experts in the field.
In this podcast, we talk about the following 9 important points:
[Read more…] about ITIT – an acronym helping you get started in the pharma industryAs statisticians, we are one of the most capable professionals to understand and to relay the right information to the general public about the most talked-about situation – the Corona Virus.
In today’s episode, I want to express what’s on my mind and on my heart about this topic. It’s a bit of an unusual episode, as I’m very passionate about the topic. You can agree or disagree with my thinking. Please let me know what you think about it.
I discuss my learnings, my reflection about this, and what it says about us as statisticians. I covering:
[Read more…] about Learnings from the COVID crisis for statisticiansMany statisticians stay in the statistics department for their entire career. But not Stephen Pyke. After climbing the corporate ladder in statistics very high at GSK, his career
Stephen shared some important learnings from his career during the PSI strategy day in 2019. In today’s episode, Stephen and I discuss the main points of his presentation and the take-away learnings for every statistician – even if you don’t work in a large pharma company. We specifically cover following questions:
[Read more…] about Problems for statisticians to take onThere are lots of buzzwords floating around and especially with the FDA having a bigger focus on RWE it’s top of mind for many stakeholders. Many teams in the different pharma organizations concentrate on this
Do you know what your external profile is?
Do you know how to improve it?
In today’s episode, Liz Cole and I will dive deep into a topic called content marketing. It’s kind of meta, since this podcast itself originates on these ideas. Does this sound frightening or disturbing? It shouldn’t.
Listen to our conversation and understand:
[Read more…] about How and why to increase your external profile!
